Analysts predict that Redhill Biopharma Ltd. (NASDAQ:RDHL) will report ($0.72) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Redhill Biopharma’s earnings, with estimates ranging from ($0.80) to ($0.66). Redhill Biopharma posted earnings of ($0.70) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 2.9%. The business is scheduled to issue its next quarterly earnings results on Monday, November 13th.
According to Zacks, analysts expect that Redhill Biopharma will report full year earnings of ($2.58) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.46). For the next financial year, analysts expect that the firm will post earnings of ($2.28) per share, with EPS estimates ranging from ($2.50) to ($2.05). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Redhill Biopharma.
RDHL has been the topic of several analyst reports. UBS AG initiated coverage on Redhill Biopharma in a research note on Wednesday, September 13th. They issued a “reduce” rating on the stock. Zacks Investment Research upgraded Redhill Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Roth Capital set a $27.00 target price on Redhill Biopharma and gave the company a “buy” rating in a research note on Monday, July 31st. HC Wainwright set a $33.00 target price on Redhill Biopharma and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, Seaport Global Securities initiated coverage on Redhill Biopharma in a research note on Friday, October 6th. They issued a “buy” rating and a $19.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Redhill Biopharma currently has an average rating of “Buy” and a consensus target price of $23.35.
Redhill Biopharma (NASDAQ:RDHL) traded down $0.06 on Friday, reaching $8.79. The company’s stock had a trading volume of 21,119 shares, compared to its average volume of 77,200. Redhill Biopharma has a 52 week low of $8.16 and a 52 week high of $12.65.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/05/zacks-brokerages-expect-redhill-biopharma-ltd-rdhl-will-announce-earnings-of-0-72-per-share.html.
Several hedge funds have recently modified their holdings of the company. Family Management Corp grew its stake in shares of Redhill Biopharma by 51.5% during the second quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after acquiring an additional 8,750 shares during the last quarter. D.A. Davidson & CO. grew its stake in shares of Redhill Biopharma by 10.0% during the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after acquiring an additional 4,000 shares during the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of Redhill Biopharma by 10.8% during the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 2,500 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Redhill Biopharma by 13.6% during the second quarter. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 1,440 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Redhill Biopharma during the first quarter worth about $276,000. Institutional investors and hedge funds own 10.98% of the company’s stock.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Redhill Biopharma Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Redhill Biopharma Ltd. and related companies.